ProGem1: A phase I/II study of a first-in-class nucleotide, Acelarin, in patients with advanced solid tumors

被引：1
|
作者：
Ghazaly, Essam Ahmed
Rizzuto, Ivana
Gabra, Hani
Habib, Nagy A.
Leonard, Robert C. F.
Wasan, Harpreet
McGuigan, Christopher
Blagden, Sarah Patricia
机构：
[1] Queen Mary Univ London, Barts Canc Inst, Ctr Haematooncol, London, England
[2] Univ London Imperial Coll Sci Technol & Med, NIHR Wellcome Trust Imperial Clin Res Facil, London, England
[3] Univ London Imperial Coll Sci Technol & Med, Dept Oncol, London, England
[4] Cardiff Univ, Sch Pharm & Pharmaceut Sci, Cardiff CF10 3AX, S Glam, Wales
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.2531
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2531
引用
收藏
页数：1
相关论文
共 50 条
  • [1] ProGem1: Phase I first-in-human study of the novel nucleotide NUC-1031 in adult patients with advanced solid tumors.
    Ghazaly, Essam Ahmed
    Joel, Simon
    Gribben, John G.
    Mohammad, Tariq
    Emiloju, Oluwadunni
    Stavraka, Chara
    Hopkins, Tom
    Gabra, Hani
    Wasan, Harpreet
    Habib, Nagy A.
    Leonard, Robert C. F.
    McGuigan, Christopher
    Slusarczyk, Magdalena
    Blagden, Sarah Patricia
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [2] Final results of ProGem1, the first in-human phase I/II study of NUC-1031 in patients with solid malignancies.
    Blagden, Sarah Patricia
    Rizzuto, Ivana
    Stavraka, Chara
    O'Shea, Daniel
    Suppiah, Puvan
    Patel, Markand
    Sukumaran, Ajithkumar
    Loyse, Naomi
    Bharwani, Nishat
    Rockall, Andrea
    Gabra, Hani
    El-Bahrawy, Mona
    Wasan, Harpreet
    Leonard, Robert C. F.
    Habib, Nagy A.
    Gribben, John G.
    Ghazaly, Essam Ahmed
    McGuigan, Christopher
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [3] Phase I study of YM155, a first-in-class survivin suppressant, in patients with advanced solid tumors in Japan
    Nakagawa, K.
    Satoh, T.
    Okamoto, I.
    Miyazaki, M.
    Morinaga, R.
    Tsuya, A.
    Hasegawa, Y.
    Terashima, M.
    Ueda, S.
    Fukuoka, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [4] First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors
    Razak, Albiruni R. Abdul
    Mau-Soerensen, Morten
    Gabrail, Nashat Y.
    Gerecitano, John F.
    Shields, Anthony F.
    Unger, Thaddeus J.
    Saint-Martin, Jean R.
    Carlson, Robert
    Landesman, Yosef
    McCauley, Dilara
    Rashal, Tami
    Lassen, Ulrik
    Kim, Richard
    Stayner, Lee-Anne
    Mirza, Mansoor R.
    Kauffman, Michael
    Shacham, Sharon
    Mahipal, Amit
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (34) : 4142 - +
  • [5] Phase I Pharmacokinetic and Pharmacodynamic Study of the First-in-Class Spliceosome Inhibitor E7107 in Patients with Advanced Solid Tumors
    Eskens, Ferry A. L. M.
    Ramos, Francisco J.
    Burger, Herman
    O'Brien, James P.
    Piera, Adelaida
    de Jonge, Maja J. A.
    Mizui, Yoshiharu
    Wiemer, Erik A. C.
    Carreras, Maria Josepa
    Baselga, Jose
    Tabernero, Josep
    CLINICAL CANCER RESEARCH, 2013, 19 (22) : 6296 - 6304
  • [6] Phase I Study of Enavatuzumab, a First-in-Class Humanized Monoclonal Antibody Targeting the TWEAK Receptor, in Patients with Advanced Solid Tumors
    Lam, Elaine T.
    Eckhardt, S. Gail
    Messersmith, Wells
    Jimeno, Antonio
    O'Bryant, Cindy L.
    Ramanathan, Ramesh K.
    Weiss, Glen J.
    Chadha, Manpreet
    Oey, Abbie
    Ding, Han Ting
    Culp, Patricia A.
    Keller, Stephan F.
    Zhao, Vivian Y.
    Tsao, L. Claire
    Singhal, Anil
    Holen, Kyle D.
    Von Hoff, Daniel
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01) : 215 - 221
  • [7] Phase 1 Study of first-in-class dUTPase inhibitor, TAS-114 in combination with capecitabine in patients with advanced solid tumors
    LoRusso, P.
    Miller, K.
    Shields, A.
    Saito, K.
    Yoshida, K.
    Aoyama, T.
    Winkler, R.
    Benedetti, F.
    Lenz, H. J.
    EUROPEAN JOURNAL OF CANCER, 2016, 69 : S119 - S119
  • [8] A Phase I Study of ABC294640, a First-in-Class Sphingosine Kinase-2 Inhibitor, in Patients with Advanced Solid Tumors
    Britten, Carolyn D.
    Garrett-Mayer, Elizabeth
    Chin, Steven H.
    Shirai, Keisuke
    Ogretmen, Besim
    Bentz, Tricia A.
    Brisendine, Alan
    Anderton, Kate
    Cusack, Susan L.
    Maines, Lynn W.
    Zhuang, Yan
    Smith, Charles D.
    Thomas, Melanie B.
    CLINICAL CANCER RESEARCH, 2017, 23 (16) : 4642 - 4650
  • [9] Phase 1 study of first-in-class dUTPase inhibitor, TAS-114 in combination with S-1 in patients with advanced solid tumors
    Aoyama, T.
    Fasolo, A.
    Stathis, A.
    Sessa, C.
    Hollebecque, A.
    Soria, J. C.
    Pastorino, A.
    Sobrero, A. S. Alberto
    Van Laethem, J. L.
    Saito, K.
    Yoshidas, K.
    Winkler, R.
    Benedetti, F.
    Gianni, L.
    EUROPEAN JOURNAL OF CANCER, 2016, 69 : S117 - S118
  • [10] A phase I extension study of BBI608, a first-in-class cancer stein cell (CSC) inhibitor, in patients with advanced solid tumors
    Jonker, Derek J.
    Stephenson, Joe
    Edenfield, William Jeffery
    Supko, Jeffrey G.
    Li, Youzhi
    Li, Wei
    Hitron, Matthew
    Leggett, David
    Kerstein, David
    Li, Chiang
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345